Search Results

Noramco announced its launch of the Noramco Group, a newly created comprehensive North American-based supply chain solution including subsidiaries Purisys, Noramco, and the newly acquired drug product CDMO, Halo Pharma.

Noramco, a leading global active pharmaceutical ingredients manufacturer, specializing in controlled substances, announced it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals.

Noramco, LLC, a leading North American producer of controlled substance and specialty bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, today announced it has reactivated its previously filed Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the active pharmaceutical ingredient methylnaltrexone bromide.

Cambrex, a leading global contract development and manufacturing organization, has completed the sale of its Drug Product Business Unit to Wilmington, Delaware based Noramco.

Noramco, LLC today announced it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the active pharmaceutical ingredient lisdexamfetamine dimesylate (Lisdex/LDX).

Pharmaron Beijing Co., Limited announced that it has entered into a definitive Asset Purchase Agreement to acquire the Coventry API manufacturing site in the United States from Noramco.

Two Organizations Will Build on Strengths to Address Differentiated End-Use Markets

Joint effort focuses on enhancing absorption, release profile, bioavailability and delivering higher CBD efficacy in convenient finished dosages

According to recent study by nova one advisor, the U.S. high potency active pharmaceutical ingredients market size was exhibited at USD 6.95 billion in 2023